Cookson Peirce & Co
CADL icon

Cookson Peirce & Co’s Candel Therapeutics CADL Stock Holding History

Cookson Peirce & Co’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-60,000
Closed -$618K – 335
2026
Q2 		$618K Buy
+60,000
New +$453K 0.02% 237

Other funds holding CADL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Tanager Wealth Management
Tanager Wealth Management Goring On Thames, United Kingdom $1.2B AUM 12% 1-Year Est. Return
ACPLP
ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Torrey Growth & Income Advisors
Torrey Growth & Income Advisors Del Mar, California $297M AUM 36.15% 1-Year Est. Return

Cookson Peirce & Co's CADL Position: Q3 2026 in Review

Cookson Peirce & Co sold out of Candel Therapeutics (CADL) in Q3 2026, closing a stake of 60,000 shares — an estimated $618K sold.

Cookson Peirce & Co first reported a position in CADL in Q2 2026 and held it in 1 quarter. The position peaked at $618K in Q2 2026. 46 funds tracked by Wall St. Rank hold CADL as of Q3 2026.

  • Cookson Peirce & Co reported no remaining Candel Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Cookson Peirce & Co sold 60,000 Candel Therapeutics shares in Q3 2026, an estimated $618K.
  • Cookson Peirce & Co first reported a position in Candel Therapeutics in Q2 2026 and held it in 1 quarter.
  • Cookson Peirce & Co's Candel Therapeutics position peaked at $618K in Q2 2026.
  • 46 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.

Based on Cookson Peirce & Co's 13F filing for Q3 2026, filed 30 Oct 2026.